Impact of Intravenous Lidocaine During Colorectal Surgery on Pain and Immune Functions

• Status: Recruiting
• Trial end date: 2023-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates the impact of intraoperative intravenous lidocaine administered during laparoscopic colorectal surgery on the intraoperative remifentanil consumption as well as postoperative pain and opioid requirements. It will evaluate immune cell activity for 48hours after surgical stress and general anesthesia with or without intravenous lidocaine.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ciusss de L'Est de l'Île de Montréal
• Collaborator: Foundation of Anesthesia and Resuscitation of Quebec
• Treatments: Anesthetics; Lidocaine

Criteria

Inclusion Criteria:

• ASA status I, II or III

• Patients older than 18 years

• Colonic surgery

• Classical management of ERAS program patients in our center

Exclusion Criteria:

• Arrhythmia, abnormal electrocardiographic , antiarrhythmic therapy

• Immunosuppressive treatments, corticosteroids or long-term NSAIDs (multiple weekly doses) or during preoperative 48 hours

• conversion intraoperative of a laparoscopic surgical technique to a laparotomy technique

• Pregnant women

• Inability to complete the questions related to this study

• Inability to use hydromorphone postoperative PCA

• Intolerance or allergy to lidocaine, hydromorphone or any other drug that is included in the protocol for perioperative management

Unexpected events leading to the exclusion:

• Difficult unplanned intubation

• Surgical complication requiring aggressive haemodynamic support (vasopressors, inotropes, transfusion)